Crispr Theraptc (NASDAQ:CRSP) – Equities research analysts at Oppenheimer Holdings boosted their Q2 2018 EPS estimates for Crispr Theraptc in a report issued on Monday. Oppenheimer Holdings analyst L. Cann now forecasts that the company will post earnings of ($0.68) per share for the quarter, up from their previous forecast of ($0.81). Oppenheimer Holdings has a “Market Perform” rating on the stock. Oppenheimer Holdings also issued estimates for Crispr Theraptc’s Q3 2018 earnings at ($0.67) EPS and Q4 2018 earnings at ($1.06) EPS.

Several other research firms have also commented on CRSP. Chardan Capital restated a “buy” rating on shares of Crispr Theraptc in a research report on Monday, August 14th. Barclays PLC reaffirmed a “buy” rating and set a $29.00 target price on shares of Crispr Theraptc in a report on Friday, September 8th. Cann assumed coverage on shares of Crispr Theraptc in a report on Monday, July 17th. They set a “market perform” rating for the company. Finally, SunTrust Banks, Inc. assumed coverage on shares of Crispr Theraptc in a research note on Thursday, July 13th. They issued a “hold” rating and a $16.00 target price for the company. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $23.08.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/04/q2-2018-eps-estimates-for-crispr-theraptc-raised-by-oppenheimer-holdings-crsp.html.

Crispr Theraptc (NASDAQ:CRSP) traded up 1.15% during midday trading on Wednesday, reaching $19.34. The company’s stock had a trading volume of 205,558 shares. Crispr Theraptc has a one year low of $13.75 and a one year high of $25.00. The stock’s 50 day moving average price is $18.57 and its 200-day moving average price is $18.57. The stock’s market cap is $785.03 million.

Crispr Theraptc (NASDAQ:CRSP) last issued its earnings results on Thursday, August 10th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.06. Crispr Theraptc had a negative net margin of 406.61% and a negative return on equity of 47.46%. The company had revenue of $3.60 million during the quarter, compared to the consensus estimate of $3.29 million. The company’s quarterly revenue was up 350.0% compared to the same quarter last year.

Hedge funds have recently modified their holdings of the business. IHT Wealth Management LLC acquired a new stake in Crispr Theraptc in the first quarter valued at approximately $110,000. Wells Fargo & Company MN increased its position in shares of Crispr Theraptc by 459.7% in the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after buying an additional 6,560 shares in the last quarter. ARK Investment Management LLC purchased a new stake in shares of Crispr Theraptc in the second quarter valued at approximately $206,000. Vanguard Group Inc. purchased a new stake in shares of Crispr Theraptc in the second quarter valued at approximately $273,000. Finally, Monashee Investment Management LLC increased its position in shares of Crispr Theraptc by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock valued at $473,000 after buying an additional 15,000 shares in the last quarter. Institutional investors own 23.90% of the company’s stock.

In related news, CEO Rodger Novak sold 18,470 shares of the company’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $20.76, for a total value of $383,437.20. Following the completion of the transaction, the chief executive officer now owns 1,148,007 shares of the company’s stock, valued at approximately $23,832,625.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kurt Von Emster sold 88,011 shares of the company’s stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $19.79, for a total value of $1,741,737.69. The disclosure for this sale can be found here. Insiders have sold a total of 625,615 shares of company stock worth $11,727,715 over the last 90 days. Insiders own 39.98% of the company’s stock.

About Crispr Theraptc

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Earnings History and Estimates for Crispr Theraptc (NASDAQ:CRSP)

Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.